Total N=47 | EC group N=29 | LC group N=18 | |
---|---|---|---|
Age | |||
year, Median [range] | 68 [33-86] | 69 [33-86] | 66.5 [48-79] |
Gender | |||
Male/Female | 28/19 | 15/14 | 13/5 |
Tumor location | |||
Rs/Ra/Rb | 1/8/38 | 1/7/21 | 0/1/17 |
Stage | |||
I | 24 (51.1) | 16 (55.2) | 8 (44.4) |
II | 8 (17.0) | 4 (13.8) | 4 (22.2) |
III | 9 (19.1) | 5 (17.2) | 4 (22.2) |
IV | 5 (10.6) | 4 (13.8) | 1 (5.6) |
Other | 1 (2.1) | 0 | 1 (5.6) |
Approach and surgery | |||
Lap-LAR | 38 (80.9) | 22 (75.9) | 16 (88.9) |
Open-LAR | 4 (8.5) | 4 (13.8) | 0 |
Lap-LAR(Trans-anal) | 3 (6.4) | 3 (10.3) | 0 |
Open-LAR(Trans-anal) | 2 (4.3) | 0 | 2 (11.1) |
Adjuvant chemotherapy | |||
Yes (%) | 9 (19.2) | 3 (10.3) | 6 (33.3) |
Neoadjuvant chemotherapy | |||
Yes (%) | 1 (2.1) | 1 (3.5) | 0 (0) |
Interval between creation and closure of stoma | |||
day, Median [range] | 79 [15-371] | 58 [15-90] | 107.5 [91-371] |